Physicians' Academy for Cardiovascular Education
"There are 3 patients with residual inflammatory risk for every patient with residual cholesterol risk," says prof. Ridker. Learn how perspectives on inflammation in atherosclerosis have changed from the1970s up until now and how (novel) anti-inflammatory therapies may reduce CVD risk.
Slides as educational service to PACE members.
On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality. "Ultimately, the inflammation hypothesis is going to yield great dividends for our patients", concluded prof. Libby.
"There are 3 patients with residual inflammatory risk for every 1 patients with residual cholesterol risk," says prof. Ridker. What are current and future therapies to lower inflammation in these patients with residual inflammatory risk?
What is the role of inflammation in the occlusion of coronary arteries? Prof. Lüscher presents findings from studies on this topic and discusses outcomes of trials with anti-inflammatory therapies.
Slides as educational service to PACE members.
Slides as educational service to PACE members.
Slides as educational service to PACE members.
Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.
Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.
